BiomX (PHGE) Research & Development (2019 - 2026)
BiomX (PHGE) posted Research & Development of -$315000.0 for Q1 2026, down 101.6% sequentially from $19.7 million in Q4 2025, and down 106.0% YoY from $5.2 million in Q1 2025.
BiomX (PHGE) Research & Development (2019 - 2026) Analysis & Trends
BiomX has reported Research & Development for 8 years, with the latest figure at -$315000.0 in Q1 2026.
- Quarterly Research & Development fell 106.0% year-over-year to -$315000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.6 million (up 27.12% YoY) and the FY2025 annual result came in at $21.3 million, down 13.67% from the prior year.
- Research & Development eased to -$315000.0 in Q1 2026 per PHGE's latest filing, from $19.7 million in the prior quarter.
- Over five years, Research & Development peaked at $19.7 million in Q4 2025 and troughed at -$12.9 million in Q4 2023.
- A 5-year average of $3.8 million and a median of $4.6 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development sank 503.72% in 2023, then jumped 207.96% in 2025.
- Over 5 years, Research & Development stood at $3.2 million in 2022, then tumbled by 503.72% to -$12.9 million in 2023, then jumped by 149.48% to $6.4 million in 2024, then surged by 207.96% to $19.7 million in 2025, then plunged by 101.6% to -$315000.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered -$315000.0, $19.7 million, and $280000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | -315,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -315,000.00 |
| Dec 31, 2025 | 19.65 Mn |
| Sep 30, 2025 | 280,000.00 |
| Jun 30, 2025 | 5.01 Mn |
| Mar 31, 2025 | 5.25 Mn |
| Dec 31, 2024 | 6.38 Mn |
| Sep 30, 2024 | 849,000.00 |
| Jun 30, 2024 | 6.90 Mn |
| Dec 31, 2023 | -12.90 Mn |
| Sep 30, 2023 | 5.64 Mn |
| Jun 30, 2023 | 3.82 Mn |
| Mar 31, 2023 | 4.56 Mn |
| Dec 31, 2022 | 3.20 Mn |
| Sep 30, 2022 | 3.54 Mn |
| Jun 30, 2022 | 4.58 Mn |
| Mar 31, 2022 | 4.93 Mn |
| Dec 31, 2021 | 6.57 Mn |
| Sep 30, 2021 | 6.61 Mn |
| Jun 30, 2021 | 3.82 Mn |
| Mar 31, 2021 | 5.67 Mn |